Mina Nikanjam - Concepedia

Author

Mina Nikanjam

University of California San Diego ORCID

Also Known As

Jincheng Yang, M Nikanjam, M. Nikanjam, Mina Nikanjam, Nikanjam, Mina

103

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

University of California San Diego Moores Cancer Center University of California, Los Angeles UC San Diego Health System University of Southern California

About

Mina Nikanjam is an author at University of California San Diego specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	553
2	Health Sciences	4	4	135
3	Engineering	2	2	177
4	Natural Sciences	1	1	70
5	Public Health	1	1	47

Mina Nikanjam

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Nature Communications	2020	276
Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme Mina Nikanjam, Andrew R. Gibbs, C. Anthony Hunt, Journal of Controlled Release NanomedicineNeuro-oncologySynthetic Nano-ldlEngineeringDrug Targeting	2007	157
Synthetic Nano-Low Density Lipoprotein as Targeted Drug Delivery Vehicle for Glioblastoma \nMultiforme Mina Nikanjam, Eleanor A. Blakely, Kathleen A. Bjornstad, eScholarship (California Digital Library)	2006	115
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study Jason K. Sicklick, Shumei Kato, Ryosuke Okamura, Genome Medicine	2021	83
ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways Thuc Le, Soumya Poddar, Joseph Capri, Nature Communications Hematological MalignancyCell RegulationOncogenic AgentNatural SciencesMixed-phenotype Acute Leukemia	2017	70
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity Shumei Kato, Ryosuke Okamura, Yuichi Kumaki, OncoImmunology	2020	65
Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients Sonoko Kawakatsu, Mina Nikanjam, Mark T. Lin, Cancer Chemotherapy and Pharmacology Adult Oncology PatientsTherapeutic Drug MonitoringOncologyMedicineHigh-dose Methotrexate	2019	59
Dosing<i>de novo</i>combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers Sariah Liu, Mina Nikanjam, Razelle Kurzrock Oncotarget Drug TargetPharmacotherapyTargeted Drug CombinationsOncologyClinical Trials	2016	56
Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients Lindsey M. Charo, Ramez N. Eskander, Ryosuke Okamura, Molecular Oncology Clinical ImplicationsGynecologyPathologyGynecology OncologyOvarian Cancer	2020	47
Targeting fusions for improved outcomes in oncology treatment Mina Nikanjam, Ryosuke Okamura, Donald A. Barkauskas, Cancer	2019	39

Page 1